Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the 2020 Evercore ISI HealthCONx Conference on December 1 at 3:30 p.m. ET. The event will be accessible via a live webcast on the Company’s website, with a replay available for 30 days post-presentation. Lantheus is a leader in diagnostic and therapeutic agents, offering products like DEFINITY®, TechneLite®, AZEDRA®, and RELISTOR®. The Company is headquartered in North Billerica, Massachusetts, with additional offices across North America and Europe.
- None.
- None.
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the 2020 Evercore ISI HealthCONx Conference at 3:30 p.m. ET on Tuesday, December 1.
To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.
